The global Hypopituitarism Diagnostics Market is expected to garner a market value of US$ 250 Million in 2023 and is expected to accumulate a market value of US$ 447.41 Million by registering a CAGR of 6% in the forecast period 2023-2033. The market for Hypopituitarism Diagnostics registered a CAGR of 4% in the historical period 2017-2022.

The strong relation between hypopituitarism and growth hormone deficiency is projected to push the market growth. The human growth hormone helps to stimulate regeneration, reproduction, and growth. Hormonal deficiency is a very serious concern for children and adults, further pushing the increasing research and development activities. For instance, in October 2019, Pfizer Inc. and its partner OPKO Health Inc. announced that its Phase III study investigating Somatrogon in pre-pubertal children with human growth hormone met its primary endpoint of non-inferiority to daily somatropin.

Request a report sample to gain comprehensive insights @ https://www.futuremarketinsights.com/reports/sample/rep-gb-16373

Furthermore, various start-ups are launching various ways to treat this rare condition. One such startup is Eli, which is a Canadian FemTech start-up developing an at-home device that can capture daily hormone fluctuations from saliva and an app to provide insights tailored to each user’s unique profile. Hormones are core to women’s reproductive and general health, yet they remain a black box. Eli unlocks this box and puts women’s daily hormonal data in women’s hands. The company develops an at-home device that captures hormone fluctuations in saliva and an app that gives women the information they want to own their health decisions, every day and across life.

Key Takeaways from the Market Study

  • From 2018-2022, the hypopituitarism diagnostics market grew at a CAGR of 4%
  • The global hypopituitarism diagnostics market is expected to grow with a 6% CAGR during 2023-2033.
  • As of 2033, the Hypopituitarism Diagnostics Market is expected to reach US$ 447.41 Million
  • According to the FMI analysis, hospitals account for the largest market share
  • North America is expected to possess 25% market share for the Hypopituitarism Diagnostics market
  • Asia Pacific is predicted to increase significantly throughout the forecast period, with a CAGR of 5% during the forecast period.

“Due to the hectic life patterns of the citizens working in cities, there has been an observed increase in stress and sleeplessness. These challenges are emerging as the main factor for the deteriorating health in the urban population by disrupting the hormonal balance in the human body,” says an FMI analyst.

Market Competition

Key players in the Hypopituitarism Diagnostics market are Abbott Laboratories, Becton, Dickinson and Company, BioMerieux, Bio-Rad Laboratories Inc., Danaher Corporation, Siemens AG, Hologic Inc., Qiagen NV, F. Hoffmann-La Roche AG, and Thermo Fisher Scientific.

  • In January 2022, Pfizer Inc. and OPKO Health, Inc. announced that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL) for the Biologics License Application (BLA) for somatrogon. Somatrogon is an investigational once-weekly long-acting recombinant human growth hormone for the treatment of growth hormone deficiency (GHD) in pediatric patients. Pfizer is evaluating the FDA’s comments and will work with the agency to determine an appropriate path forward.

More Insights Available

FMI, in its new offering, presents an unbiased analysis of the global hypopituitarism diagnostics market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023-2033.

The study reveals essential insights on the basis of Test Type (Hormone Stimulation Tests, MRI or CT Scan, Visual Field Check, Insulin Tolerance Test), End User (Academic Research Institutes, Hospitals, Specialty Clinics, Others) & region.

Key Companies Profiled:

  • Abbott Laboratories
  • Becton, Dickinson, and Company
  • BioMerieux
  • Bio-Rad Laboratories Inc.
  • Danaher Corporation
  • Siemens AG
  • Hologic Inc.
  • Qiagen NV
  • F. Hoffmann-La Roche AG
  • Thermo Fisher Scientific

Key Segments Profiled in the Hypopituitarism Diagnostics Industry Survey

By Test Type:

  • Hormone Stimulation Tests
  • MRI or CT Scan
  • Visual Field Check
  • Insulin Tolerance Test

By End User:

  • Specialty Clinics
  • Hospitals
  • Academic Research Institutes
  • Others

By Region:

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa